Sorting through the extensive and confusing roles of sortilin in metabolic disease

KA Mitok, MP Keller, AD Attie - Journal of Lipid Research, 2022 - ASBMB
Sortilin is a post-Golgi trafficking receptor homologous to the yeast vacuolar protein sorting
receptor 10 (VPS10). The VPS10 motif on sortilin is a 10-bladed β-propeller structure …

Role of lipoprotein (a) in atherosclerotic cardiovascular disease: A review of current and emerging therapies

IS Alhomoud, A Talasaz, A Mehta… - … : The Journal of …, 2023 - Wiley Online Library
Abstract Lipoprotein (a), or Lp (a), is structurally like low‐density lipoprotein (LDL) but differs
in that it contains glycoprotein apolipoprotein (a)[apo (a)]. Due to its prothrombotic and …

Lipoprotein (a) and cardiovascular disease: a missing link for premature atherosclerotic heart disease and/or residual risk

H Melita, AA Manolis, TA Manolis… - Journal of …, 2022 - journals.lww.com
Lipoprotein (a) or lipoprotein “little a”[Lp (a)] is an under-recognized causal risk factor for
cardiovascular (CV) disease (CVD), including coronary atherosclerosis, aortic valvular …

Relationship of low-density lipoprotein-cholesterol and lipoprotein (a) to cardiovascular risk: The Multi-Ethnic Study of Atherosclerosis (MESA)

R Rikhi, A Hammoud, N Ashburn, AC Snavely… - Atherosclerosis, 2022 - Elsevier
Background and aims Plasma low-density lipoprotein cholesterol (LDL-C) and lipoprotein
(a)(Lp (a)) are both associated with coronary heart disease (CHD). This study investigated …

The biogenesis and transport of triglyceride-rich lipoproteins

L Zhang, X Wang, XW Chen - Trends in Endocrinology & Metabolism, 2024 - cell.com
Triglyceride-rich lipoproteins (TRLs) play essential roles in human health and disease by
transporting bulk lipids into the circulation. This review summarizes the fundamental …

PCSK9 inhibitors in the management of cardiovascular risk: a practical guidance

X Jia, M Al Rifai, A Saeed, CM Ballantyne… - Vascular Health and …, 2022 - Taylor & Francis
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are potent medications in
the toolkit for treatment of atherosclerotic cardiovascular disease. These agents have been …

Association between lipoprotein (a), fibrinogen and their combination with all-cause, cardiovascular disease and cancer-related mortality: findings from the NHANES

Z Wang, X Yan, L Fang, J Tang, J Zhang - BMC Public Health, 2024 - Springer
Background There is evidence indicating that both lipoprotein (a)[Lp (a)] and fibrinogen (FIB)
are associated with mortality, However, the impact of their combination on mortality has not …

[PDF][PDF] Impact of alirocumab/evolocumab on lipoprotein (a) concentrations in patients with familial hypercholesterolaemia: A systematic review and meta-analysis of …

H Dai, Y Zhu, Z Chen, R Yan, J Liu, Z He… - Endokrynologia …, 2023 - researchgate.net
Introduction: Familial hypercholesterolaemia (FH) is a common hereditary genetic disorder,
characterized by elevated circulating low-density lipoprotein cholesterol (LDL-C) and …

Lipoprotein (a) as a novel biomarker for predicting adverse outcomes in ischemic heart failure

B Zhang, Y Xu, X Huang, T Sun, M Ma… - Frontiers in …, 2024 - frontiersin.org
Background Lipoprotein (a)[Lp (a)] is an independent risk factor for atherosclerotic
cardiovascular disease (ASCVD). However, the association between Lp (a) and adverse …

[PDF][PDF] Comparison of serum lipoprotein (a) levels in young and middle-aged patients presenting for the first time with ST-elevation myocardial infarction: a single …

S Usalp, E Altuntaş, B Bağırtan, KÖ Karabay - Cardiovasc J Afr, 2023 - researchgate.net
Abstract Background: Lipoprotein (a)[Lp (a)] is associated with coronary artery disease due
to its atherogenic and thrombogenic nature. In this study, we aimed to compare the level of …